The unique applicability of the human placenta to the Adverse Outcome Pathway (AOP) concept: the placenta provides fundamental insights into human organ functions at multiple levels of biological organization.

Adverse Outcome Pathway Co-culture Ex vivo models In vitro models Monoculture Perfusion model Placenta Trophoblast

Journal

Reproductive toxicology (Elmsford, N.Y.)
ISSN: 1873-1708
Titre abrégé: Reprod Toxicol
Pays: United States
ID NLM: 8803591

Informations de publication

Date de publication:
09 2020
Historique:
received: 02 12 2019
revised: 27 07 2020
accepted: 31 07 2020
pubmed: 10 8 2020
medline: 8 3 2022
entrez: 10 8 2020
Statut: ppublish

Résumé

Despite the short lifespan of the human placenta, the proper formation and function of the organ is of crucial importance for fetal development. Placental dysfunction increases the risk of complications for mother and child during pregnancy and childbirth and beyond as it predisposes to fetal programming. The placenta is an upstream organ of the fetus. It performs the functions of fetal lungs, liver, intestines, kidneys and glands as long as these organs are not fully functional. Furthermore, it is the only human organ that is non-invasively available either after elective abortion or after birth. This is a crucial point given that the conceptual framework of Adverse Outcome Pathway (AOP) requires data on organ function. In vitro and ex vivo placental studies, combined with epidemiological and clinical data on pregnant women, newborns, and infants can uniquely cover all levels of information needed to develop new AOPs and complement existing AOPs related to reproductive toxicity and beyond. To stimulate further research in this area and to support researchers in future studies dealing with the development of AOPs related to the placenta, this review first gives a brief description of placental structure, placental development and relevant pregnancy diseases. The state of knowledge about the available placental models, their particularities and limitations are briefly discussed. Finally, the use of placental research for the development of AOPs is presented with an illustrative example.

Identifiants

pubmed: 32768559
pii: S0890-6238(20)30188-X
doi: 10.1016/j.reprotox.2020.07.014
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-281

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Claudia Gundacker (C)

Institute of Medical Genetics, Medical University Vienna, Vienna, Austria. Electronic address: claudia.gundacker@meduniwien.ac.at.

Isabella Ellinger (I)

Institute for Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH